Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 25,93 € (+109,96%). La mediana è 25,93 € (+109,96%).
| Acquista |
13 |
| Mantieni |
0 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
MediWound: VALUE study for EscharEx as decisive near-term catalyst
MediWound presented its bromelain platform at the H.C. Wainwright conference, highlighting NexoBrid revenue potential and the upcoming VALUE phase III study for EscharEx as key drivers. The VALUE study (216 patients) includes an interim analysis at ~65% recruitment; various sample-size adjustments are possible, and topline data are expected about three months after the interim analysis. The company is expanding production capacity, expects European approval in mid‑2027, and points to commercial progress with NexoBrid as well as a BARDA-linked partnership with Vericel. » Altro su de.investing.com
MediWound calls extraordinary general meeting for Feb. 19
MediWound has called an extraordinary general meeting for Feb. 19, 2026, and on Jan. 15, 2026 filed the related notice and a proxy statement with the SEC. Registered shareholders will receive voting materials and a proxy card. The filings give meeting details but do not disclose specific agenda items; the documents refer to existing registration statements on Forms S-8 and F-3. » Altro su de.investing.com
MediWound: study shows NexoBrid removes over 90% of traumatic tattoos
A prospective study at Sheba Medical Center found that MediWound’s enzymatic preparation NexoBrid reduced the pigmented wound surface by an average of 92.5% in 15 patients (96% for abrasion injuries, 84% for blast injuries). The treatment was administered at the bedside under sedation within 24 hours and showed no treatment-related adverse events in early follow-up. MediWound recently raised around $30 million via a direct offering, received approval in Australia and is planning production and capacity expansions; one analyst raised the price target. » Altro su de.investing.com
MediWound raises $30 million through registered direct placement
MediWound sold 1,734,105 ordinary shares at $17.30 per share in a registered direct placement, raising about $30 million. The transaction was led by a U.S. investment fund and other healthcare-focused investors; H.C. Wainwright & Co. served as sole placement agent. Net proceeds are intended to fund precommercial activities for EscharEx, expand manufacturing capacity and general corporate purposes. The company also reported TGA approval of NexoBrid in Australia and new study data on the importance of wound bed preparation. » Altro su de.investing.com
MediWound presents growth plan and cites supply bottlenecks for NexoBrid
MediWound presented its growth strategy at the H.C. Wainwright conference, focusing on the phase-3 study of EscharEx and expansion of production capacity. The company reported supply chain problems with NexoBrid and plans a new manufacturing site in the US as well as an additional facility in Europe to address the shortages. Partnerships with BARDA and the DOD, cash of $33 million and a potential $30 million from warrants support the commercialization plans; a BARDA tender is expected in Q4 2025. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 3,15 Mln | 31,81% |
| Utile lordo | 897,86K | 17,60% |
| Utile netto | -5,29 Mln | 133,89% |
| EBITDA | -7,2 Mln | 287,68% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 159,14 Mln € |
Numero di azioni | 12,91 Mln |
Massimo/minimo a 52 settimane | 20,10 € - 10,73 € |
| Dividendi | No |
Beta | 0,14 |
Rapporto P/E | -7,45 |
Rapporto PEG | 0,94 |
Rapporto P/B | 5,53 |
Rapporto P/S | 17,48 |
Profilo aziendale
MediWound Ltd., una società biofarmaceutica, sviluppa, produce e commercializza soluzioni innovative e bioterapeutiche per la riparazione e la rigenerazione dei tessuti. Commercializza NexoBrid, un prodotto biofarmaceutico per la rimozione dell'escara, ovvero tessuto morto o danneggiato, in adulti con ustioni termiche profonde a spessore parziale e totale, destinato ai centri per ustionati e alle unità per ustioni degli ospedali. La società sviluppa inoltre EscharEx, che ha completato le sperimentazioni cliniche di fase II per il debridement di ferite croniche e di altre ferite difficili da guarire; e MW005, che è in fase I/II per il trattamento del carcinoma basocellulare a basso rischio. MediWound Ltd. è stata fondata nel 2000 e ha sede a Yavne, in Israele.
| Nome | MediWound |
| CEO | Ofer Gonen |
| Sede centrale | Yavne,
hm Israele |
| Sito web | |
| Settore | Beni di prima necessità |
| Industria | Prodotti per la cura della persona |
| Quotazione in borsa | 20/03/2014 |
| Dipendenti | 121 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | MDWD |
Frankfurt | M8W.F |